Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

Table 1 Baseline laboratory parameters of all included patients

Parameter	Unit	Median	Min	Max	Reference range
Rivaroxaban	ng ml⁻¹	103	20	425
CRP^a	mg dl⁻¹	0.7	0.1	16.5	0.0–0.5
pH		7.42	7.33	7.49	7.37–7.45
FI (Clauss)	mg dl⁻¹	303	240	524	210–400
FI (immun)	mg dl⁻¹	365	272	591	200–400
ATIII (FIIa)	%	86	47	101	79–112
D-Dim^a	μg l⁻¹	994	191	3186	0–500
FII	%	115	65	146	70–120
FV	%	102	55	172	70–120
FVII	%	88	50	173	70–120
FVIII^a	%	261	94	343	70–150
vWF^a	%	288	149	509	58–174
FIX	%	104	65	161	70–120
FX	%	84	41	122	70–120
FXI	%	85	42	138	70–120
FXII	%	100	54	125	70–120
FXIII	%	116	49	130	70–120
Plasminogen	%	88	44	119	75–150
Leukocytes	×10⁹ l⁻¹	8	3	13	4.0–10.0
Erythrocytes^a	×10¹² l⁻¹	4.2	3.2	4.7	4.4–5.9
Haemoglobin	g l⁻¹	131	93	141	130–177
Haematocrit^a	l l⁻¹	0.37	0.27	0.40	0.4–0.52
Platelets	×10⁹ l⁻¹	172	84	344	150–380

CRP C-reactive protein, pH potential hydrogen, FI fibrinogen, blood coagulation factor I, immun immunological method, AT-III anti-thrombin III, FI-FXIII blood coagulation factors I-XIII, D-Dim d-dimers, vWF von Willebrand Factor. Highlighting: ^aout of reference range

ISSN: 1477-9560